Willow Biosciences Announces Annual General And Special Meeting Voting Results

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS/

CALGARY, AB, June 1, 2020 /CNW/ - Willow Biosciences Inc. ("Willow" or  "the Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting (the "Meeting") of shareholders held on June 1, 2020. A total of 36,983,055 common shares, representing approximately 46.88% of Willow's issued and outstanding shares, were represented at the Meeting.

The following nominees were elected as directors of Willow for the ensuing year, with the specific voting results being as follows:

	Votes For		Votes Withheld
Director	#	%	#	%
Dr. Peter Seufer- Wasserthal	34,517,839	99.99%	3,735	0.01%
Trevor Peters	34,517,839	99.99%	3,735	0.01%
Dr. Fotis Kalantzis	34,517,839	99.99%	3,735	0.01%
Donald Archibald	34,517,839	99.99%	3,735	0.01%
Sadiq H. Lalani	34,517,834	99.99%	3,740	0.01%
Al Foreman	34,517,834	99.99%	3,740	0.01%

In addition, shareholders approved the appointment of KPMG LLP as the Company's auditor for the ensuing year (99.95% of the votes cast being in favour).

Shareholders also ratified and approved the adoption of a new stock option plan of the Company and authorized its continuation for a three-year period from the date of the Meeting (99.95% of the votes cast being in favour).

About Willow Biosciences Inc.

Willow is a Canadian biotechnology company based in Calgary, Alberta, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow's current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow's science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments. Willow's manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs.

Reader Advisories

This news release may include forward-looking information that involves risk and uncertainty. For this purpose, any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements often contain terms such as "may", "will", "should", "anticipate", "expects" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Willow assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

SOURCE Willow Biosciences Inc.

For further information, please visit our website at www.willowbio.com or contact: Trevor Peters, President and Chief Executive Officer, T: [phone], E: [email protected]; Troy Talkkari, CFA, Vice President, Corporate Development, T: [phone], E: [email protected], 3655 36th Street NW, Calgary, AB T2L 1Y8